Business Wire

Nexo Unveils Zero-interest Credit with 0% APR and No Fees

Share

Nexo, the premier digital assets wealth platform, today announced the launch of Zero-interest Credit (ZiC), now joining the Nexo Credit Line as a flagship borrowing solution. ZiC enables Bitcoin and Ethereum holders to access liquidity at 0% interest through a fixed-duration term, free from the risk of premature forced liquidation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108785934/en/

Zero-interest Credit by Nexo

Previously available through Nexo’s Private and OTC services, structured zero-interest borrowing has been used by Nexo’s private channels and is now broadly available through Zero-interest Credit. In 2025, it has enabled access to more than $140 million in liquidity.

A broad solution for investors, traders, and businesses

Zero-interest Credit is designed for clients who want liquidity without sacrificing their long-term positioning. It supports BTC and ETH holders who prefer not to sell, affluent investors managing the timing of taxable events or funding major purchases, active traders pursuing market opportunities with defined risk, and businesses using digital assets to finance operations or strategic plans.

Built for peace of mind

ZiC brings a level of predictability rarely seen in crypto-backed credit. Instead of monitoring LTV ratios or worrying about market-driven liquidations, clients borrow at 0% interest with a structure that stays intact. Every ZiC position comes with a predefined repayment path that is fully visible from day one. Clients select the term and amount, and ZiC’s built-in Minimum Repayment Price ensures the loan cannot be liquidated mid-term, while the Maximum Repayment Price enables clients to lock in gains up to that level. At maturity, repayment is straightforward, with the option to settle in stablecoins or with collateral based on where the market stands relative to their predefined range. And for those who want continued exposure, ZiC Renewal makes it possible to extend the arrangement with refreshed terms, without unwinding or re-establishing the loan.

Borrowers today want liquidity that is cost-efficient, clear, and free from the uncertainty of liquidation risk,” said Elitsa Taskova, Chief Product Officer at Nexo. “Zero-interest Credit gives them exactly that—a fully predefined borrowing structure they can rely on from start to finish.

Setting a new standard for responsible crypto lending

As borrowing demand grows and major digital assets consolidate their role as the industry’s strongest collateral base, the market is shifting from interest-driven credit to structured models that prioritize predictability and client control. Crypto-collateralised lending reached $73.59 billion in Q3 2025, up 38.5% quarter-over-quarter and surpassing the previous cycle peak1 — reflecting stronger collateral quality and deeper institutional participation.

As a pioneer of crypto-backed credit — and today the world’s #2 crypto lender2 — Nexo continues to shape the industry. Zero-Interest Credit positions Nexo at the forefront of responsible credit innovation — delivering a solution shaped for the borrowing landscape as it stands today.

About Nexo

Nexo is a premier digital assets wealth platform designed to empower clients to grow, manage, and preserve their crypto holdings. Our mission is to lead the next generation of wealth creation by focusing on customer success and delivering tailored solutions that build enduring value, supported by 24/7 client care.

Since 2018, Nexo has provided unmatched opportunities to forward-thinking clients in over 150+ jurisdictions. With over $11 billion in AUM and $371 billion processed, we bring lasting value to millions worldwide. Our all-in-one platform combines advanced technology with a client-first approach, offering high-yield flexible and fixed-term savings, crypto-backed loans, sophisticated trading tools, and liquidity solutions, including the first crypto debit/credit card. Built on deep industry expertise, a sustainable business model, robust infrastructure, stringent security, and global licensing, Nexo champions innovation and long-lasting prosperity.

Official website: nexo.com

1Coinspeaker - Crypto Lending Hits $73.6B Record as DeFi Captures Two-Thirds of Market

2Galaxy Research - The State of Crypto Leverage – Q3 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108785934/en/

Contacts

communications@nexo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye